The CDKN2A-CDKN2B rs4977756 polymorphism and glioma risk: a meta-analysis.

The association between the rs4977756 single nucleotide polymorphism (SNP) and glioma risk has been studied, but these studies have yielded conflicting results. In order to explore this association, we performed a meta-analysis. A comprehensive literature search was performed using PubMed and EMBASE database. Six articles including 12 case-control studies in English with 12022 controls and 6871 cases were eligible for the meta-analysis. Subgroup analyses were conducted by ethnicity and source of controls. Our meta-analysis found that rs4977756 polymorphism was associated with glioma risks in homozygote, heterozygote, dominant, recessive and additive genetic models (GG versus AA: OR=1.55, 95% CI=1.42-1.69, Ph=0.996, I(2)=0.0%; AG versus AA: OR=1.20, 95% CI=1.12-1.28, Ph=0.934, I(2)=0.0%; recessive model: OR=1.39, 95% CI=1.28-1.50, Ph=0.995, I(2)=0.0%; dominant model: OR=1.29, 95% CI=1.21-1.37, Ph=0.923, I(2)=0.0%; additive model: OR=1.24, 95% CI=1.19-1.30, Ph=0.966, I(2)=0.0%). Moreover, our results suggested that CDKN2A-CDKN2B rs4977756 polymorphism was associated with a notable increased risk of glioma in Europeans. However, in Asians, we could not come to a conclusion because of lack of studies. Sensitivity analysis showed the omission of any study made no significant difference. No evidence of publication bias was produced. Our meta-analysis suggested that rs4977756 polymorphism was associated with increased risk of glioma. Moreover, additional studies should be further investigated to draw a more accurate conclusion.